{"entity":{"id":"tenofovir","kind":"drug","name":"Tenofovir (disoproxil and alafenamide)","aka":["tenofovir disoproxil fumarate","TDF","tenofovir alafenamide","TAF"],"tldr":"Tenofovir is an antiviral tablet for hepatitis B and HIV. Someone with current or past hepatitis B who needs certain cancer treatments takes it to stop the virus flaring up.","summary":"The Viread (tenofovir disoproxil fumarate) label covers HIV-1 infection with other antiretrovirals and chronic hepatitis B; the Vemlidy (tenofovir alafenamide) label covers chronic hepatitis B with compensated liver disease. ASCO's 2020 provisional clinical opinion on hepatitis B and cancer summarises guidance that patients with chronic infection or past exposure receiving higher-risk chemotherapy \"require antiviral prophylaxis with tenofovir or entecavir\". Viread was first approved on 26 October 2001 and Vemlidy on 10 November 2016.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Tenofovir_disoproxil","links":[{"label":"US label (DailyMed): Viread","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33fd6418-fbdc-42ca-a50d-ce2a476a5418"},{"label":"US label (DailyMed): Vemlidy","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72e6b33c-0351-4070-9172-eeaa186c01d2"},{"label":"Hwang et al., Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update (J Clin Oncol 2020)","url":"https://doi.org/10.1200/JCO.20.01757"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["lymphoma-tx-hepatitis-b-reactivation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Viread / Vemlidy","modality":"Antiviral (nucleotide analogue reverse transcriptase inhibitor, oral)","supportive":true,"mechanism":"A nucleotide analogue that inhibits hepatitis B virus and HIV-1 reverse transcriptase.","approvals":[{"region":"US","year":2001,"indication":"Viread: HIV-1 infection and chronic hepatitis B","note":"NDA 021356 (Drugs@FDA)"},{"region":"US","year":2016,"indication":"Vemlidy: chronic hepatitis B with compensated liver disease","note":"NDA 208464 (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tenofovir/","neighbours":{"term":[{"id":"lymphoma-tx-hepatitis-b-reactivation","kind":"term","name":"Hepatitis B reactivation before rituximab and other anti-CD20 antibodies","route":"/terms/lymphoma-tx-hepatitis-b-reactivation/"}]}}